Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06031805 | PRostate Olaparib Real World Evidence Study(PROWESs) | active not recruiting | — | 159 | AstraZenecaINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06073821 | Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | active not recruiting | Phase 3 | 652 | BeOne MedicinesINDUSTRY | 21 | Sep 28, 2026 |
| NCT06075953 | DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | recruiting | Phase 2 | 400 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06110793 | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06120283 | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 433 | BeOne MedicinesINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06148038 | CBD for Breast Cancer Primary Tumors | recruiting | Phase 1 | 84 | Medical University of South CarolinaOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06149481 | Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06192758 | Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device(VOYAGER) | active not recruiting | N/A | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06252675 | Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 2 | 30 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06298877 | Frailty, Quality Of Life and Early Reversal of Temporary Defunctioning Stoma in Ovarian Cancer(FOLERO) | recruiting | N/A | 475 | Sahar SalehiOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06331299 | A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer(UTOPIA) | active not recruiting | Phase 3 | 99 | UroGen Pharma Ltd.INDUSTRY | 7 | Sep 28, 2026 | clinicaltrials |
| NCT06350318 | Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | recruiting | Phase 2 | 43 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06388967 | Pancreatic Cancer Detection Consortium(PCDC) | recruiting | — | 2,000 | City of Hope Medical CenterOTHER | 3 | Sep 28, 2026 | clinicaltrials |
| NCT06396598 | Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer | completed | N/A | 116 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06421675 | Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma(EMBRACE) | recruiting | Phase 2 | 40 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06425991 | A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma(MajesTEC-10) | active not recruiting | Phase 1 | 108 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT06454149 | Cohort Study for Gastric MALT Lymphoma(HUG-MALToma) | recruiting | — | 300 | Seoul National University HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06470971 | Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial | recruiting | Phase 2 | 40 | Yuanquan YangOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06472817 | Social Determinants of Migrant Health Factors Impacting Prostate Cancer Care and Survivorship Among Sub-Saharan African and Caribbean Immigrant Men | enrolling by invitation | — | 80 | Mayo ClinicOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06484062 | Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes | recruiting | Phase 1 | 54 | National Cancer Institute (NCI)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06496256 | Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial | recruiting | N/A | 84 | Palette Life Sciences, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06514794 | A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | recruiting | Phase 2 | 125 | Allotera TherapeuticsINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT06524375 | A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period(BRAVE) | active not recruiting | Phase 2 | 118 | Genentech, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06586957 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 238 | NiKang Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer(RAINFOL-02) | active not recruiting | Phase 3 | 584 | GenmabINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT06623422 | A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | recruiting | Phase 3 | 680 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 28, 2026 | clinicaltrials |
| NCT06625203 | A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology(MOSAIC) | active not recruiting | — | 7,000 | OWKINUNKNOWN | 4 | Sep 28, 2026 | clinicaltrials |
| NCT06651229 | A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms | active not recruiting | Phase 1 | 85 | Janssen Research & Development, LLCINDUSTRY | 3 | Sep 28, 2026 | clinicaltrials |
| NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | recruiting | Phase 1 / Phase 2 | 258 | BeOne MedicinesINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT06726161 | Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC(GPC3) | recruiting | Phase 1 / Phase 2 | 590 | RayzeBio, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06742996 | A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | recruiting | Phase 3 | 300 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT06787339 | Capecitabine in Low Risk Triple Negative Breast Cancer(Calorite) | recruiting | Phase 2 | 198 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06803771 | Surveillance of Pancreatic Health After Diabetes Diagnosis(SAFE-D) | recruiting | N/A | 5,000 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06833073 | A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | recruiting | Phase 2 | 308 | Merck Sharp & Dohme LLCINDUSTRY | 19 | Sep 28, 2026 | clinicaltrials |
| NCT06833658 | Effects of Aromatherapy With Essential Oils on Anxiety and Depression in Perioperative Patients With Pancreatic Cancer | completed | N/A | 156 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06902402 | Evaluation of Safety and Efficacy of Supportan® Drink | recruiting | N/A | 135 | Fresenius Kabi Taiwan Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06919965 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer(MoonRISe-3) | recruiting | Phase 3 | 220 | Janssen Research & Development, LLCINDUSTRY | 15 | Sep 28, 2026 | clinicaltrials |
| NCT06931717 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy(ARCH) | recruiting | Phase 3 | 390 | ETOP IBCSG Partners FoundationNETWORK | 9 | Sep 28, 2026 | clinicaltrials |
| NCT06958432 | Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II) | recruiting | Phase 2 / Phase 3 | 430 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT06961006 | A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | recruiting | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 28, 2026 | clinicaltrials |
| NCT06973187 | A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 24 | Sep 28, 2026 | clinicaltrials |
| NCT06997497 | A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | recruiting | Phase 3 | 477 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 28, 2026 | clinicaltrials |
| NCT07013435 | A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship | recruiting | N/A | 254 | Massachusetts General HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07014293 | Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors | recruiting | N/A | 254 | Massachusetts General HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07039474 | The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy | recruiting | — | 120 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07048353 | CD30 CAR-T in the Treatment of CD30 Positive Lymphoma(CAR-T，MTD) | suspended | Early Phase 1 | 15 | Shandong Qilu Cell Therapy Engineering Technology Co., LtdINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
Data updated 3 days agoSource updated Sep 28, 2026source: clinicaltrials